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Clinical breakpoints (CBPs) are not available for the Cryptococcus neoformans-Cryptococcus gattii species complex. MIC distri-
butions were constructed for the wild type (WT) to establish epidemiologic cutoff values (ECVs) for C. neoformans and C. gattii
versus amphotericin B and flucytosine. A total of 3,590 amphotericin B and 3,045 flucytosine CLSI MICs for C. neoformans (in-
cluding 1,002 VNI isolates and 8 to 39 VNII, VNIII, and VNIV isolates) and 985 and 853MICs for C. gattii, respectively (includ-
ing 42 to 259 VGI, VGII, VGIII, and VGIV isolates), were gathered in 9 to 16 (amphotericin B) and 8 to 13 (flucytosine) laborato-
ries (Europe, United States, Australia, Brazil, Canada, India, and South Africa) and aggregated for the analyses. Additionally, 442
amphotericin B and 313 flucytosine MICs measured by using CLSI-YNBmedium instead of CLSI-RPMImedium and 237 Etest
amphotericin BMICs for C. neoformanswere evaluated. CLSI-RPMI ECVs for distributions originating in >3 laboratories (with
the percentages of isolates for whichMICs were less than or equal to ECVs given in parentheses) were as follows: for amphoteri-
cin B, 0.5g/ml for C. neoformans VNI (97.2%) and C. gattii VGI and VGIIa (99.2 and 97.5%, respectively) and 1g/ml for C.
neoformans (98.5%) and C. gattii nontyped (100%) and VGII (99.2%) isolates; for flucytosine, 4g/ml for C. gattii nontyped
(96.4%) and VGI (95.7%) isolates, 8g/ml for VNI (96.6%) isolates, and 16g/ml for C. neoformans nontyped (98.6%) and C.
gattiiVGII (97.1%) isolates. Other molecular types had apparent variations inMIC distributions, but the number of laboratories
contributing data was too low to allow us to ascertain that the differences were due to factors other than assay variation. ECVs
may aid in the detection of isolates with acquired resistance mechanisms.
Among the non-Candida yeasts, members of the Cryptococcusneoformans-Cryptococcus gattii complex have been the most
common species recovered among clinical isolates (32.9% of
8,717 isolates), as well as the secondmost common cause of severe
fungal infection after Candida spp. in certain regions (38, 41).
Infections caused byCryptococcus neoformans var. grubii (serotype
A) are seen worldwide among immunocompromised hosts, fol-
lowed by Cryptococcus neoformans var. neoformans (serotype D)
(2). On the other hand, C. gattii (serotypes B and C) is geograph-
ically more restricted and causes infections among immunocom-
promised as well as nonimmunocompromised patients, and the
infections are more difficult to treat (31, 35). Irrespective of the
species, cryptococcal infections are associated with highmortality
rates (12.7%). By use of molecular methodologies, eight major
molecular types have been identified among the four serotypes
and their hybrids (2, 4, 19, 46). C. neoformans comprises molecu-
lar types VNI and VNII (both belonging to serotype A), VNIII (an
AD hybrid), and VNIV (serotype D), while C. gattii comprises
VGI (serotype B) andVGII, VGIII, and VGIV (among serotypes B
and C). Molecular type VGII has been of particular interest in
recent years due to the emergence of the novel strains/subtypes
VGIIa, VGIIb, and VGIIc (5, 29). Molecular types VNI to VNIV
have also been designated AFLP1 to AFLP3, and types VGI to
VGIV have been designated AFLP4 to AFLP7 (19).
Although several newer antifungal agents are available, the
conventional deoxycholate formulation of amphotericin B (espe-
cially in resource-limited settings) and its lipid formulations re-
main important therapeutic choices for the systemic treatment of
cryptococcal infections caused by C. neoformans and C. gattii (32,
35). Among the three lipid amphotericin B formulations, lipo-
somal amphotericin B has been licensed for the treatment of cryp-
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tococcal meningitis among AIDS patients (32, 35). The polyenes
bind to ergosterol in the cellmembrane, leading to pore formation
and eventually to cell death (49). In contrast, flucytosine inhibits
DNA replication and protein synthesis. In polyene-resistant Can-
dida and Cryptococcus isolates, ergosterol content has been lower
than in susceptible isolates (28). Several enzymes (purine-cytosine
permease, cytosine deaminase, uracil phosphoribosyltransferase)
are involved in the flucytosine mode of action as well as fungal
resistance to this agent (14, 50, 51). The combination of flucyto-
sine and amphotericin B is one of the treatments recommended
for cryptococcal infections (35). However, relapses are frequent.
The availability of reference methodologies has enabled the
recognition of resistant isolates as well as the proposal of clinical
breakpoints (CBPs) and epidemiologic cutoff values (ECVs) for
Candida spp. and Aspergillus spp. with regard to most available
antifungal agents by both the Clinical and Laboratory Standards
Institute (CLSI) and the Subcommittee on Antifungal Suscepti-
bility Testing of the European Committee on Antibiotic Suscep-
tibility Testing (AFST-EUCAST) (15–17, 37, 39, 40, 42, 43). CBPs
are based onMIC distributions, pharmacokinetic and pharmaco-
dynamic (PK/PD) parameters, animal studies, and clinical out-
comes of therapy, while ECVs are based mostly on MIC distribu-
tions. CLSI MICs are1 g/ml (amphotericin B) and8 g/ml
(flucytosine) for most C. neoformans and C. gattii isolates (3, 13,
18, 23, 36, 45), but acquired resistance is frequent during flucyto-
sinemonotherapy (1, 22). In the past few years, antifungal suscep-
tibility differences have been reported between these two species,
as well as among the molecular types and serotypes (6–8, 19, 24,
45, 47). However, neither CBPs nor ECVs are available for either
C. neoformans orC. gattii versus amphotericin B or flucytosine. In
the absence of CBPs, ECVs could help to characterize the suscep-
tibilities of these species to amphotericin B, its lipid formulations,
and flucytosine and tomonitor the emergence of strains withmu-
tations that could lead to reduced susceptibility to these antifungal
agents.
We are proposing ECVs (see “Definitions” below) for ampho-
tericin B and flucytosine against C. neoformans (VNI and non-
typed isolates) and C. gattii (VGI, VGII, and nontyped isolates).
The purposes of the study were (i) to define the wild-type (WT)
(population of isolates in a species-drug combination with no
detectable acquired resistancemechanisms [11, 48]) susceptibility
endpoint distributions (see “Definitions” below) of each species/
molecular type and agent combination by using aggregated CLSI-
RPMI broth MICs of amphotericin B and flucytosine gathered in
8 to 16 laboratories (3,590 to 3,045 MICs for C. neoformans and
985 to 853 MICs for C. gattii, species/molecular type and agent/
combination dependent) in Europe, the United States, Australia,
Brazil, Canada, India, and South Africa and (ii) to propose ECVs
on the basis of data originating fromat least 3 of these laboratories.
The 442 amphotericin B and 313 flucytosine MICs that were ob-
tained using the alternative CLSI-yeast nitrogen base (CLSI-YNB)
broth (9, 10) and the 237 amphotericin B Etest MICs for C. neo-
formans were analyzed separately.
MATERIALS AND METHODS
Isolates. Each isolate from unique clinical specimens was tested at each
medical center: the University of Texas Health Science Center, San Anto-
nio, TX; the University of Iowa College of Medicine, Iowa City, IA; the
University of Texas Health Science Center, Houston, TX; the Centers for
Disease Control and Prevention, Atlanta, GA; Duke University Medical
Center, Durham, NC; VCU Medical Center, Richmond, VA; Canisius
Wilhelmina Hospital, Department of Medical Microbiology and Infec-
tious Diseases, Nijmegen, TheNetherlands; theHPAMycology Reference
Laboratory, Kingsdown, Bristol, UnitedKingdom; the InnsbruckMedical
University, Innsbruck, Austria; the Hospital General Universitario Gre-
gorio Marañón, Madrid, Spain; Servicio de Micología, Centro Nacional
deMicrobiología, Instituto de Salud Carlos III, CtraMajadahonda-Pozu-
elo, Spain; Facultat deMedicina, IISPV, URV, Reus, Spain; the University
of Alberta, Edmonton, Alberta, Canada; the Adolfo Lutz Institut, São
Paulo State, Brazil; Vallabhbhai Patel Chest Institute, University of Delhi,
Delhi, India; the Instituto de Pesquisa Clinica Evandro Chagas-
FIOCRUZ, Rio de Janeiro, Brazil; and the Women’s and Children’s Hos-
pital, North Adelaide, Australia. Species and molecular types were identi-
fied at each medical center using standard methodologies (8, 19, 20, 24,
33, 47). We have aggregated the maximum available CLSI data from each
laboratory and agent (a total of 3,590 to 3,045 MICs of amphotericin B
and flucytosine MICs for C. neoformans [including those for 1,002 VNI
isolates] and 985 and 853MICs for C. gattii [including those for 42 VGIIc
to 259VGI isolates]) (8, 19, 20, 24, 33, 47). A set of 313 flucytosine and 442
amphotericin B MICs obtained using CLSI-YNB broth instead of the
CLSI-RPMImedium (9), as well as 237 Etest amphotericin BMICs for C.
neoformans, were also available; both of these sets were analyzed sepa-
rately. One or both of the quality control (QC) isolates (Candida parap-
silosis ATCC 22019 and Candida krusei ATCC 6258) were used by the
participating laboratories (9, 10) (see Table 1).
Antifungal susceptibility testing. In order to include MIC results in
the total set of available aggregated CLSI data from the participant labo-
ratories (see Table 2), amphotericin B and flucytosine MICs were ob-
tained at each center by following the CLSI M27-A3 broth microdilution
method (standard RPMI-1640 broth [0.2% dextrose]; final inoculum
concentrations ranging from 0.4 103 to 5 103 CFU/ml; 72 h of incu-
bation); MICs were the lowest drug concentrations that produced either
50% (flucytosine) or 100% (amphotericin B) inhibition of growth com-
pared to that of the control (9). For isolates grown in YNB broth, testing
conditions and interpretation ofMICswere otherwise identical. The set of
amphotericin B EtestMICs was obtained by following themanufacturer’s
instructions, and endpoints were rounded up to the nearest 2-fold dilu-
tion. MIC data for the two QC reference strains, utilized during the years
of testing in each center, were obtained by following the CLSI M27-A3
broth microdilution method (9, 10).
Definitions. The WT population is that population of isolates/MICs
in a species-drug combination with no detectable acquired resistance
mechanisms (11, 48). The highest WT susceptibility endpoint has been
defined as either the WT cutoff value (COWT) or the ECV, which is the
critical drug concentration that may identify those strains with decreased
susceptibility or serve as an early warning of emerging changes in the
patterns of susceptibility of organisms to the agent being evaluated (11,
48). The latter term has been used previously in similar fungal reports
(15–17, 37, 39, 40, 42, 43).
Data analysis. Several amphotericin B and flucytosine MIC distribu-
tions were obtained for C. neoformans: (i) aggregated CLSI-RPMI data
from 13 and 10 laboratories, respectively, for isolates that were not mo-
lecularly typed (referred to below as “nontyped isolates”) and (ii) from 2
to 4 laboratories for molecular types VNI to VNIV (referred to below as
“typed isolates”), (iii) single-laboratory CLSI-YNB data, and (iv) single-
laboratory amphotericin B Etest data (see Table 2). The final WT distri-
butions for C. gattii were (i) aggregated CLSI-RPMI amphotericin B and
flucytosine data from 4 laboratories for nontyped isolates and (ii) data
from 2 to 5 laboratories for VGI to VGIV (also referred to below as “typed
isolates”) (Table 2). The aggregatedMIC distributions obtained in at least
three laboratories were used to define ECVs by the statisticalmethod (48),
where themodeled population is based on fitting a normal distribution at
the lower end of the MIC range, working out the mean and standard
deviation of that normal distribution, and using those parameters to cal-
culate theMICs that capture at least 95%, 97.5%, and 99%of themodeled
Espinel-Ingroff et al.
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WT population. The MIC value that captured 95% of the observed
population (“visual” method) was calculated as in previous studies (15–
17, 37, 39, 40, 42).
RESULTS AND DISCUSSION
For susceptibility testing to be clinically relevant, the test result
should predict with some reliability the clinical outcome for an
infected patient treated with the specific agent evaluated; this test
result is the CBP (11, 26). CBPs are established on the basis of
clinical trial data (in particular, clinical and microbiological out-
comes versus the MIC for the infecting pathogen), global suscep-
tibility surveillance, resistance mechanisms, and PK/PD parame-
ters frommodel systems. On the other hand, the ECV is based on
MIC distributions and is the highest MIC that belongs to the WT
(isolates with no detectable acquired resistance mechanisms) dis-
tribution.While the CBP predicts the clinical outcome of therapy,
the ECV could monitor the emergence of strains with reduced
susceptibility (due tomutations) to the agent being evaluated, e.g.,
the reduced susceptibility of C. neoformans or C. gattii to either
flucytosine or amphotericin B. No CBPs for any antifungal agent
against eitherC. neoformans orC. gattii are available, owing to the
paucity of data on PK/PD and clinical outcomes compared to
MICs. In addition, attempts to correlate in vitro results with clin-
ical outcome have not been successful (12, 30). The amphotericin
B and flucytosine ECVs established in the present study for C.
neoformans and C. gattiimay aid in the evaluation of clinical iso-
lates by identifying those strains thatmay have acquired resistance
mechanisms and may serve as an early warning of emerging
changes in the susceptibility patterns of these organisms. Even
though the frequencies of cryptococcal meningitis and other
infections have decreased with the use of antiretroviral thera-
pies in developed countries, these infections are still a major
problem among immunosuppressed patients and in certain
geographical areas. Amphotericin B and flucytosine continue
to be the primary therapeutic agents for cryptococcal infec-
tions (32, 35).
Variability is expected when MICs from different laboratories
are compared, despite standardization efforts (9, 10). Table 1
shows theMICdata obtained in participant laboratories for one or
both QC isolates (overall range and individual modes), C. parap-
silosis ATCC 22019 and C. krusei ATCC 6258, when clinical iso-
lates were tested. Although most ranges were within the CLSI es-
tablished limits (98 to 100%) for the twoQC strains (10), a certain
degree of mode variability was observed (mostly 2-fold dilu-
tion). Intralaboratory reproducibility was also excellent (10 and
20 replicate tests) in the two laboratories using either the CLSI-
YNB medium or Etest methodology (data not shown in Table 1).
The modal variability among the participant laboratories for QC
strains reflected the modal MIC differences for the clinical Cryp-
tococcus sp. isolates. Similarmodal variability has been observed in
previous ECV studies for Aspergillus spp. with several antifungal
agents (15–17) and may indicate individual interpretations of
MIC endpoints or may result from the use of different lots of
antifungal powders, or both.
The aggregated amphotericin B and flucytosine MIC distribu-
tions for C. neoformans and C. gattii (for nontyped and typed
isolates) are shown in Table 2, which also lists the single-labora-
tory distributions for C. neoformans (YNB and Etest data). The
highest amphotericin B modal MICs (0.5 g/ml) measured in
RPMI medium were for C. gattii nontyped and VGII isolates; the
modalMIC for all other distributions was 0.25g/ml. Amphoter-
icin B modes observed in the data from most individual contrib-
uting laboratories were similar (0.25 or 0.5 g/ml) for both spe-
cies. The exceptions were the mode (0.12 g/ml) from one
laboratory for nontyped C. neoformans isolates and for VNIII and
VNIV typed isolates, but the number of isolates was low for the
latter two sets. Overall, our values reflect amphotericin B MIC50s
or geometric means (0.25 and 0.5 g/ml) obtained in previous
studies for similar sets of nontyped and typed isolates (7, 12, 23,
36, 45); results have been higher (0.5g/ml) in other studies (3,
13). For C. neoformans, amphotericin B MICs measured in YNB
appeared to be higher (mode, 1 g/ml) than those measured in
RPMI medium. In contrast, amphotericin B MICs by the Etest
were lower (mode, 0.12g/ml) (Table 2).We are not sure why the
YNB and Etest data are different from those obtained using RPMI
broth, because each set was from a single laboratory, which pre-
cluded comparisons. However, both modes were different from
those observed in 12 of the 13 laboratories using RPMI medium
for the similar set of nontyped isolates. In prior reports, ampho-
tericin B MIC50s have been either 0.12 g/ml (12) or 1 g/ml (3)
by Etest and 0.25g/ml by use of YNB (7). These results underline
the variability of susceptibility test results using different method-
ologies as well as the need to evaluate MIC distributions before
ECV definition.
Flucytosine modes were more dependent on the species, mo-
lecular type, and medium (Tables 2 and 3). The modes for C.
neoformans nontyped and VNI isolates were the same (4 g/ml),
TABLE 1 MICs for quality control strains used in 13 (flucytosine) and 16 (amphotericin B) laboratories according to the CLSI broth microdilution
methoda
QC isolate and antifungal agentb
QCMIC (g/ml)
range (mode)
% of CLSI MICs
within range
MIC (g/ml) obtained in 13 to 16 laboratories
Range Modes
Candida parapsilosis ATCC 22019
AMB 0.5–4 (2) 91.7 0.12–2c 0.5, 0.5, 0.5, 0.5, 0.5, 1, 1, 1, 1, 1, 1, 1, 2, 2, ND,d ND
FCT 0.12–0.5 (0.25) 97.9 0.12–0.5 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.25, 0.25, 0.25, ND, ND
Candida krusei ATCC 6258
AMB 1–4 (2) 100 1–2 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, ND, ND
FCT 8–32 (16) 99.6 8–32 8, 8, 8, 8, 8, 16, 16, ND, ND, ND
a MICs were determined as described by CLSI document M27–A3 using RPMI–1640 broth (9, 10).
b AMB, amphotericin B; FCT, flucytosine.
c MICs were outside the range in one laboratory for QC isolate C. parapsilosis ATCC 22019 2% of the time (1 of 49 times).
d ND, not determined or value obtained using the CLSI-YNB medium broth or Etest.
Amphotericin B and Flucytosine ECVs for Cryptococcus
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but more variability was observed for C. gattii, with the lowest
mode for the small set of nontyped isolates (1 g/ml) and the
highest (8 g/ml) for two of the three VGII subtypes (VGIIa and
VGIIc). Ourmode data for flucytosine susceptibility reflect differ-
ences found betweenC. neoformans (MIC50, 4g/ml) andC. gattii
(MIC50, 2 g/ml), as well as differences among genotypes of the
latter species (MIC50s, 1 to 4 g/ml) (7, 45), where the highest
value was that for VGII. YNB yielded a higher mode (8 g/ml)
than that for the similar set of nontyped C. neoformans isolates
measured in RPMI medium (Table 2). Since this value was based
on results froma single laboratory, it is not clear if this discrepancy
is medium or reader related. However, modes in each participant
laboratory for C. neoformans (both nontyped and typed isolates)
were either 2 or 4g/ml (data not shown in Tables 2 and 3). Based
on these data and the wide geographical range over which MICs
were collected in the present study, we surmise that the data are
valid.
Table 3 shows the proposed amphotericin B and flucytosine
ECVs for the aggregated distributions of C. neoformans and C.
gattii (typed or nontyped isolates) where the data originated in
three or more laboratories (using the methodology that com-
prised 95%, 97.5%, and 99% of the modeled population).
The CLSI amphotericin B ECVwas 1g/ml for distributions ofC.
neoformans andC. gattii nontyped and VGII isolates (encompass-
ing 98.5, 100, and 99.2% of the isolates, respectively) and 0.5
g/ml for VNI, VGI, and VGIIa isolates (encompassing 97.25%,
TABLE 2 Wild-type MIC distributions of amphotericin B and flucytosine for the Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or
molecular
type
Antifungal
agentb Mediumc Genotypedd
No.
of
labse
Total
no. of
isolates
No. of isolates for which the MIC (g/ml)f was:
0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64
C. neoformans AMB RPMI N 13 2,526 4 68 159 985 918 355 34 3
VNI Y 4 1,002 2 12 229 511 220 26 2
VNII Y 2 8 1 6 1
VNIII Y 2 15 2 7 4 1 1
VNIV Y 2 39 1 20 15 2 1
All isolates Both 3,590 6 83 416 1,521 1,141 375 36 3
C. neoformans AMB YNB N 1 442 5 27 132 271 7
Etest N 1 237 13 8 116 94 5 1
C. neoformans FCT RPMI N 10 1,981 50 75 138 260 497 527 342 65 6 21
VNI Y 4 1,002 2 4 11 28 98 286 422 117 10 3 21
VNII Y 2 8 3 2 1 2
VNIII Y 2 15 4 8 3
VNIV Y 2 39 1 1 4 19 9 2 2 1
All isolates Both 3,045 2 54 86 170 361 792 978 471 77 11 43
C. neoformans FCT YNB N 1 313 2 5 16 86 77 104 14 3 6
C. gattii AMB RMPI N 4 130 1 22 45 52 8
VGI Y 5 259 1 4 49 164 39 2
VGIIg Y 4 122 14 35 58 14 1
VGIIa Y 3 200 2 29 111 53 5
VGIIb Y 2 106 1 11 53 38 3
VGIIc Y 2 42 8 23 11
VGIII Y 2 42 1 1 15 19 6
VGIV Y 2 84 17 57 10
All isolates Both 985 2 9 165 507 267 32 1
C. gattii FCT RPMI N 4 55 3 12 19 11 8 2
VGI Y 4 256 1 2 11 90 126 15 4 7
VGIIg Y 4 68 1 2 11 20 18 12 2 1 1
VGIIa Y 2 200 3 31 61 81 24
VGIIb Y 2 106 1 3 17 40 26 16 2 1
VGIIc Y 2 42 1 3 7 20 9 2
VGIII Y 2 42 2 7 14 12 5 1 1
VGIV Y 2 84 2 15 31 24 11 1
All isolates Both 853 1 6 30 149 253 185 161 53 5 10
a Amphotericin B and flucytosine MICs were determined by the CLSI broth microdilution method (9); amphotericin B Etest MICs were determined according to the
manufacturer’s instructions.
b AMB, amphotericin B; FCT, flucytosine.
c RPMI and YNB, RPMI-1640 and yeast nitrogen base, respectively, as described by CLSI document M27-A3 (9).
d Y, yes; N, no.
e Number of laboratories contributing data to each MIC distribution.
f The modal MIC for each distribution is underlined.
g Isolates identified as belonging to the VGII molecular type but not to one of the VGIIa, VGIIb, or VGIIc subtypes, which are examined as separate groups.
Espinel-Ingroff et al.
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99.25%, and 97.5% of the isolates, respectively). It is interesting
that an amphotericin B MIC of 2 g/ml is anecdotally believed to
be the breakpoint for resistance yet can be perceived as aWT value
here. The flucytosine ECVs for C. neoformans nontyped and VNI
distributions were 16 and 8 g/ml (encompassing 98.65% and
96.6% of the isolates, respectively). For C. gattii, flucytosine ECVs
were either 4 g/ml (nontyped and VGI isolates) or 16 g/ml
(VGII isolates), encompassing 96.45%, 95.75%, and 97.1% of the
isolates. Because only two laboratories contributed data for the
other molecularly typed isolates, and both amphotericin B and
flucytosine distributions in YNB were obtained in a single labora-
tory, ECVs were not proposed for these distributions (Table 1).
Although tentative values of 1 g/ml (amphotericin B; encom-
passing 98.4% of the isolates) and 16 g/ml (flucytosine; encom-
passing 97.1% of the isolates) can be suggested for YNB MICs
(data not shown in Table 3), additional data from other laborato-
ries using this medium are needed to corroborate these tentative
values. Visual ECVswere similar to those obtained by using95%
of the modeled population, and some higher ECVs were observed
using 95% of the modeled populations (48). Although our
newly defined amphotericin B and flucytosine ECVs are not pre-
dictors of clinical outcome, these susceptibility cutoff concentra-
tions may aid in identifying those cryptococcal strains with de-
creased susceptibility to these two agents.
The frequency of amphotericin B and flucytosine MICs above
the ECV (non-WT) differed according to the distribution ana-
lyzed (Table 4). The rate of non-WTMICs was lower for ampho-
tericin B distributions of both species (0% to 2.8%) than for flu-
cytosine (1.4% to 4.3%) (ECVs encompassing 95% of the
calculated populations). The rate of non-WT flucytosine MICs
was lower among allC. neoformans isolates (4.3%) than among all
C. gattii isolates (10.8%), but the rates of non-WT amphotericin B
MICs were almost the same for the two species (4.3% and 4.1%,
respectively). Although cryptococcal infections by these two spe-
cies are clinically similar, infections caused by C. gattii show a
delayed treatment response, and other complications, relative to
infections due to C. neoformans (21, 35). In vitro resistance to
amphotericin B (0.6% to 5.3%) and flucytosine (2.2% to 46%) has
been reported among a smaller number of C. neoformans isolates
than those in our study; although the susceptibility cutoff has been
consistent for amphotericin B (2g/ml), it has been variable for
flucytosine (8 and 32 g/ml), in the different studies (3, 13,
36, 45). All these results underscore the utility of antifungal sus-
ceptibility testing andWT cutoffs as a practical tool with which to
detect amphotericin B and flucytosine resistance among Crypto-
coccus isolates; species identification is clinically useful. These re-
sults also indicated that ECVs should be species specific and, for
this fungal group, molecular type specific.
Although the mechanisms for flucytosine resistance in C. neo-
formans have been elucidated, those for resistance to amphoteri-
cin B are poorly understood despite the usage of this drug since the
1960s (14, 22, 27, 44, 50, 51). In addition, the link between genetic
mutations inCryptococcus spp. and highMICs of these two agents
has not been determined. Susceptibility testing by M27-A3 meth-
odologies demonstrated that high MICs for C. neoformans were
predictive of clinical failure of the azoles and, to a lesser degree, of
both polyenes and flucytosine (34). Amphotericin B MICs of2
g/ml have been associated with clinical failure, a defect in the
target enzyme sterol delta 8¡7 isomerase, other mutations in the
sterol biosynthesis pathway (e.g., 5,6-desaturase), or an increase in
the efflux of the drug from the fungal cell (25, 28). Primary and
acquired resistance of C. neoformans was frequently reported
when the use of flucytosine began in the 1970s, and high flucyto-
sineMICs correlated with failure (as high as 57%) among patients
receiving this agent alone (1, 22, 50). Resistance to this agent oc-
TABLE 3 ECVs for amphotericin B and flucytosine against the
Cryptococcus neoformans-Cryptococcus gattii species complex obtained in
3 to 16 laboratories by the CLSI M27-A3 broth microdilution method
Speciesa
Antifungal
agentb
MIC (g/ml)
Calculated ECV (g/ml)
comprising the following
proportion of the
statistically modeled
population for each MIC
distributiond:
Range Modec 95% 97.5% 99%
C neoformans
Nontyped AMB 0.03–4 0.25 1 1 2
VNI 0.03–2 0.25 0.5 1 1
C neoformans
Nontyped FCT 0.125–64 4 16 16 32
VNI 0.06–64 4 8 8 16
C. gattii
(nontyped)
AMB 0.06–1 0.5 1 1 2
VGI 0.03–1 0.25 0.5 0.5 0.5
VGII 0.125–2 0.5 1 1 2
VGIIa 0.06–1 0.25 0.5 1 1
C. gattii
(nontyped)
FCT 0.25–8 1 4 8 8
VGI 0.125–64 2 4 4 4
VGII 0.25–64 2 16 16 16
a ECVs were defined only for distributions from at least three laboratories (see Table 2
for other molecular type distributions) using RPMI-1640 as described in CLSI
document M27-A3 (9).
b AMB, amphotericin B; FCT, flucytosine.
c MIC most frequently obtained for each distribution.
d ECVs defined for all isolates of each species (Table 2) were similar.
TABLE 4 Percentages of isolates of the Cryptococcus neoformans-
Cryptococcus gattii species complex above the amphotericin B and
flucytosine wild-type distribution obtained in 3 to 16 laboratories by the
CLSI M27-A3 broth microdilution method
Species and
genotypea
Antifungal
agent
ECV (g/ml) comprising the following
proportion of the statistically modeled
population (% of observations above
each statistical ECV):
95% 97.5% 99%
C. neoformans
Nontyped AMB 1 (1.5) 1 (1.5) 2 (0.1)
VNI 0.5 (2.8) 1 (0.2) 1 (0.2)
C. neoformans
Nontyped FCT 16 (1.4) 16 (1.2) 32 (1.1)
VNI 8 (3.4) 8 (3.4) 16 (2.4)
C. gattii AMB 1 (0) 1 (0) 2 (0)
VGI 0.5 (0.8) 0.5 (0.8) 0.5 (0.8)
VGII 1 (0.8) 1 (0.8) 2 (0)
VGIIa 0.5 (2.5) 1 (0) 1 (0)
C. gattii FCT 4 (3.6) 8 (0) 8 (0)
VGI 4 (4.3) 4 (4.3) 4 (4.3)
VGII 16 (2.9) 16 (2.9) 16 (2.9)
a Data from laboratories using CLSI-RPMI broth.
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curs bymutations within the pyrimidine pathway (either cytosine
deaminase or uracil phosphoribosyltransferase) specifically linked
in haploid C. neoformans cells to a single mutation at either the
FCY1 or the FCY2 gene (50). Poor correlation between amphoter-
icin B and flucytosine CLSI MICs and clinical outcome has been
reported (12), but the number of patients was low (4 to 19 in each
set of therapy success or failure groups), geometric mean MICs
were similar (0.22 to 0.39 g/ml for amphotericin B and 2.24 to
2.87 g/ml for flucytosine), and other factors could have influ-
enced the outcome (some patients were infected with HIV). It is
noteworthy that the combination of these two agents is synergistic
in vitro despite resistance to flucytosine (44). Therefore, much
needs to be examined and determined regarding the relationship
between non-WT strains and resistance mechanisms.
In conclusion, the ECVs of amphotericin B (0.5 to 1 g/ml)
and flucytosine (4 to16 g/ml) proposed in this study for the C.
neoformans-C. gattii species complex were species and molecular
type specific. Further investigation should determine the relation-
ship between the molecular mechanisms of amphotericin B and
flucytosine resistance and our proposed non-WT values. Some of
the distributions were small (especially for various C. neoformans
molecular types), and continuing surveillance should either cor-
roborate or extend the information provided in the present study.
In the absence of CBPs, these ECVs may aid in detecting non-WT
isolates that have reduced susceptibility to amphotericin B and
that harbor flucytosine resistance mechanisms. ECVs should be
included in the revised version of the CLSI M27-A3 document.
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